Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts. From the companyâs inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901. Source
No articles found.
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headq...
Spok, Inc., a wholly owned subsidiary of Spok H...
Founded in 1999, Dexcom, Inc. is the leader in transforming diabetes care and mana...
Founded in 1999, Dexcom, Inc. is the leader in ...
Eidos is a clinical stage biopharmaceutical company focused on addressing the larg...
Eidos is a clinical stage biopharmaceutical com...
Join the National Investor Network and get the latest information with your interests in mind.